Results 111 to 120 of about 38,769 (305)

Recommendations on the Proper Use of SGLT2 Inhibitors

Journal of Diabetes Investigation, 2020
The Committee on the Proper Use of SGLT2 Inhibitors
doaj   +1 more source

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature

Quality in Sport
• The purpose of research: Heart failure (HF) is an important global health concern. Despite advancements in treatment, HF remains the leading cause of hospitalization among the elderly.
Silvia Ciraolo, Agnieszka Kulczycka-Rowicka, Joanna Wojda, Katarzyna Lesiczka-Fedoryj, Anna Walczak, Zuzanna Kościuszko, Adam Sobiński, Matylda Czerwonka, Katarzyna Kurza, Julianna Podolec   +9 more
doaj   +1 more source

Applications of SGLT2 inhibitors beyond glycaemic control

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past decade, a series of large, robust clinical
Yi, Tae Won, O'Hara, Daniel V., Hocking, Samantha, Dawson, Jessica, Januszewski, Andrzej S., Lam, Carolyn S.P., McMurray, John J.V., Raichand, Smriti, Jardine, Meg J.   +8 more
core   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

Epilepsia, EarlyView.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin, Hui‐Min Huang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Research Progress of SGLT2 Inhibitors in Cancer Treatment

Xiaoyong Miao,1,* Jianing Zhang,2,* Weiyan Huang,2,* Yifei Wang,1 Aixia Jin,1 Jianping Cao,1 Zhenzhen Zhao3 1Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, People’s Republic of China; 2Student Brigade,
Jin A, Zhang J, Huang W, Cao J, Miao X, Wang Y, Zhao Z   +6 more
core  

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

Equine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom, Sanna Truelsen Lindåse, Monika Wartel, Johan Bröjer   +3 more
wiley   +1 more source

Food‐grade proteins, lipids, and fibers as potential tools to ameliorate cardiovascular disorders: A review

Food Biomacromolecules, EarlyView.
Abstract Cardiovascular diseases (CVDs) remain the leading cause of global mortality, necessitating effective preventive and adjunct therapeutic strategies beyond conventional pharmacological interventions. Although previous reviews have focused on individual nutrients or dietary patterns, this review provides a mechanism‐based, integrative perspective
Sridevi Shanmugam, Rukaiah Fatma Begum, Nirenjen Shanmugasundaram, Bhupendra Gopalbhai Prajapati, Suresh Ankul Singh, Pavithra Nagenthran, Sudarshan Singh, Kesarla Rajesh   +7 more
wiley   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors

Diabetes is a complex global healthcare burden involving multiple organ systems with its prevalence on the rise. SGLT2 inhibitors enhance glucose excretion. The objective of our literature review was to determine the association between cutaneous adverse
Claudia Borza, Patrick Dumitrescu, Alexandra Laura Mederle, Nilima Rajpal Kundnani   +3 more
core   +1 more source

The effects of SGLT2 inhibitor side chain structure on its function and side effects

, 2022
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by hyperglycemia. The pathophysiology of T2DM is complex but it is known that cells cannot use insulin effectively. The initial treatment for T2DM focuses on a healthy lifestyle, however,
Nuñez de la Rosa, Ana Karen
core